Pharma News

Keep updating your pharma knowledge
16 Jun 2016

Zydus Cadila and Turkey based Eczacibasi’s strategic collaboration for biosimilar

Zydus Cadila and Eczacibasi, a Turkish Healthcare Company have signed a strategic collaboration agreement to market biotech products in the Turkish market. The agreement involves the import of biosimilars which are currently unavailable in the country especially for the treatment of cancer and also paves the way for a long term strategic collaboration to produce and launch new products in the market.

Why Biosimilar has different approval process than generic drugs? >> View

First Biosimilar in US market >> View

Learn recent developments related to Biosimilar drugs >> View

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!